Episode
Why Ozempic keeps wowing the world
- Podcast
- ABC News Daily
- Published
- Jun 14, 2026
- Duration seconds
- 861
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/abc-news-daily-504641/episodes/why-ozempic-keeps-wowing-the-world/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/abc-news-daily-504641/why-ozempic-keeps-wowing-the-world.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured: Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University